Malignant melanoma of eyelid – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:04:21 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Malignant melanoma of eyelid – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effects of ATL001 and Nivolumab for Adults with Metastatic or Recurrent Melanoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-nivolumab-for-adults-with-metastatic-or-recurrent-melanoma/ Wed, 29 Apr 2026 14:29:42 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-nivolumab-for-adults-with-metastatic-or-recurrent-melanoma/ This clinical trial is focused on studying a type of skin cancer called metastatic or recurrent melanoma. The study is testing a new treatment approach using a personalized therapy called ATL001, which is a type of cell therapy. This therapy involves using the patient’s own immune cells, specifically T cells, which are modified to better recognize and attack cancer cells. The study also involves a medication called nivolumab, which is known by the brand name OPDIVO. Nivolumab is a type of drug that helps the immune system fight cancer by blocking a protein that stops the immune system from attacking cancer cells.

The purpose of this study is to evaluate the safety and how well the treatment works when using ATL001 alone and in combination with nivolumab. Participants in the study will receive these treatments through an infusion, which means the medication is given directly into the bloodstream through a vein. The study will monitor participants over a period of time to observe any side effects and to see how the cancer responds to the treatment. The study aims to understand if this combination can help control the cancer and improve outcomes for patients with metastatic or recurrent melanoma.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the effects of the treatment. The study will also look at changes in the size of the tumor and overall survival rates. This research is important for developing new ways to treat melanoma and potentially improve the quality of life for those affected by this disease.

]]> Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation https://clinicaltrials.eu/trial/study-of-encorafenib-binimetinib-and-pembrolizumab-for-patients-with-advanced-melanoma-with-braf-v600e-k-mutation/ Wed, 29 Apr 2026 14:28:56 +0000 https://clinicaltrials.eu/trial/study-of-encorafenib-binimetinib-and-pembrolizumab-for-patients-with-advanced-melanoma-with-braf-v600e-k-mutation/ This clinical trial is focused on studying a type of skin cancer called melanoma, specifically when it has spread to other parts of the body or cannot be removed by surgery. The study is looking at patients with a specific genetic change known as the BRAF V600E/K mutation. The trial will test the effectiveness of a combination of medications: Encorafenib, Binimetinib, and Pembrolizumab. Encorafenib is taken as a capsule, Binimetinib as a tablet, and Pembrolizumab is given through an infusion, which means it is delivered directly into the bloodstream through a vein.

The purpose of the study is to compare the effects of the combination of Encorafenib, Binimetinib, and Pembrolizumab against a placebo combined with Pembrolizumab. Participants will be randomly assigned to receive either the combination of the three medications or the placebo with Pembrolizumab. The study will last for up to 24 months, during which participants will receive regular treatments and check-ups to monitor their health and the progress of the melanoma.

This trial aims to determine if the combination of these medications can improve outcomes for patients with this specific type of melanoma. The study will also assess the safety of the medication combination and monitor any side effects that may occur. Participants will be closely observed by healthcare professionals throughout the study to ensure their well-being and to gather important information about the treatment’s effectiveness.

]]> Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy https://clinicaltrials.eu/trial/study-of-encorafenib-binimetinib-and-pembrolizumab-for-patients-with-braf-v600e-k-mutation-positive-melanoma-after-anti-pd-1-therapy/ Wed, 29 Apr 2026 14:28:40 +0000 https://clinicaltrials.eu/trial/study-of-encorafenib-binimetinib-and-pembrolizumab-for-patients-with-braf-v600e-k-mutation-positive-melanoma-after-anti-pd-1-therapy/ This clinical trial is focused on studying a type of skin cancer called melanoma, specifically in patients who have a mutation known as BRAF V600E/K. This mutation can make the cancer more aggressive and harder to treat. The study is looking at patients whose melanoma has either spread to other parts of the body or cannot be removed by surgery. These patients have already been treated with a type of therapy called anti-PD-1 therapy, which helps the immune system fight cancer, but their cancer has continued to grow.

The purpose of the study is to compare two different treatment combinations to see which is more effective. One group of participants will receive a combination of three medications: encorafenib, binimetinib, and pembrolizumab. The other group will receive a combination of two medications: nivolumab and ipilimumab. These medications are given to help the immune system target and destroy cancer cells. Encorafenib and binimetinib are taken as tablets, while pembrolizumab, nivolumab, and ipilimumab are given through an infusion into a vein.

Participants in the study will be randomly assigned to one of the two treatment groups. The study will last for a period of time, during which participants will receive their assigned treatment and be monitored regularly by the study team. The goal is to see which treatment combination works better in controlling the cancer and improving the participants’ health. The study will also look at the safety of the treatments and any side effects that may occur. Participants will have regular check-ups and tests to track their progress and the effects of the treatment.

]]>